Idexx Laboratories (IDXX) Current Deferred Revenue (2009 - 2026)

Idexx Laboratories (IDXX) has reported Current Deferred Revenue for 18 consecutive years, with $36.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 3.79% year-over-year to $36.3 million; the TTM figure through Mar 2026 stood at $36.3 million (up 3.79% YoY), while the FY2025 annual figure was $35.3 million, up 4.33% from the prior year.
• Current Deferred Revenue came in at $36.3 million for Q1 2026 at Idexx Laboratories, up from $35.3 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $40.9 million in Q1 2022, with the low at $33.8 million in Q4 2024.
• Average Current Deferred Revenue over 5 years is $37.5 million, with a median of $37.8 million recorded in 2023.
• Across the five-year window, Current Deferred Revenue decreased 9.13% in 2024 and grew 4.33% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $37.9 million in 2022, then slipped by 1.96% to $37.2 million in 2023, then slipped by 9.13% to $33.8 million in 2024, then grew by 4.33% to $35.3 million in 2025, then gained by 3.02% to $36.3 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $36.3 million, $35.3 million, and $35.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.